文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

非可除颤性心脏骤停后轻中度复苏后休克结局与温度管理的关联:HYPERION试验事后分析

Outcomes of mild-to-moderate postresuscitation shock after non-shockable cardiac arrest and association with temperature management: a post hoc analysis of HYPERION trial data.
PubMed 文献 · Ann Intensive Care · 2022-10-17
一句话结论非可除颤性心脏骤停后轻中度复苏后休克患者中,33°C低温治疗与37°C控制性正常体温相比第90天功能结局无显著差异。

该研究为HYPERION试验的事后分析,纳入法国25个ICU的581例非可除颤性心脏骤停患者,按有无复苏后休克(需血管活性药物)分组,比较低温(33°C)与控制性正常体温(37°C)对第90天脑功能分级(CPC)1或2的比例。休克组339例中,低温组159例有14例CPC 1-2,正常体温组180例有10例CPC 1-2(8.81% vs 5.56%,P=0.24);校正后也无显著差异(校正HR 1.99,95%CI 0.72-5.50,P=0.18)。第90天死亡率两组相当(83% vs 86%,P=0.43)。结论认为轻中度复苏后休克似乎与第90天功能结局或生存无关,低温治疗未伴随更差结局。

要点

  • 非可除颤性心脏骤停后轻中度复苏后休克(需血管活性药物)患者中,33°C低温组第90天CPC 1-2为8.81%,37°C正常体温组为5.56%,差异无统计学意义(P=0.24)。
  • 校正后低温组与正常体温组第90天CPC 1-2仍无显著差异(校正HR 1.99,95%CI 0.72-5.50,P=0.18)。
  • 两组第90天死亡率相当:低温组83% vs 正常体温组86%(P=0.43)。
  • 入组排除去甲肾上腺素或肾上腺素>1 µg/kg/min的患者,即仅涵盖轻中度复苏后休克。
  • 作者结论:轻中度复苏后休克似乎与第90天功能结局或生存无关,33°C低温未伴随更差结局。

适用人群与场景

  • 法国25个ICU纳入的581例非可除颤性心脏骤停患者(未撤回知情同意者)。
  • 分为复苏后休克组339例(定义为需血管活性药物)与无休克组242例。
  • 排除去甲肾上腺素或肾上腺素>1 µg/kg/min的患者,即仅限轻中度复苏后休克。

诊断标准与关键阈值

  • 复苏后休克定义:需要血管活性药物。
  • favourable functional outcome定义:第90天脑功能分级(CPC)1或2。

处置流程与药物剂量

  • 低温组目标温度33°C,对照为控制性正常体温37°C。

研究设计与关键结果

  • 研究类型:HYPERION试验数据的事后分析;样本量581例,来自法国25个ICU;人群为非可除颤性心脏骤停患者。
  • 休克组339例中,低温组159例有14例第90天CPC 1-2,正常体温组180例有10例第90天CPC 1-2(8.81% vs 5.56%,P=0.24)。
  • 校正后低温组与正常体温组第90天CPC 1-2无显著差异(校正HR 1.99,95%CI 0.72-5.50,P=0.18)。
  • 休克组第90天死亡率:低温组83% vs 正常体温组86%(P=0.43)。

证据类型、等级与局限

  • 证据类型:随机对照试验(HYPERION)的事后分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于非可除颤性心脏骤停后轻中度复苏后休克(血管活性药物需求未超过去甲肾上腺素或肾上腺素1 µg/kg/min)的患者,33°C低温治疗与37°C控制性正常体温相比,第90天功能结局和生存无显著差异。
  • 作者认为,轻中度复苏后休克似乎与第90天功能结局或生存无关,33°C低温未伴随更差结局。

指南或共识出处

  • HYPERION试验(ClinicalTrials.gov,NCT01994772)的事后分析,发表于Ann Intensive Care。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Outcomes of postresuscitation shock after cardiac arrest can be affected by targeted temperature management (TTM). A post hoc analysis of the "TTM1 trial" suggested higher mortality with hypothermia at 33 °C. We performed a post hoc analysis of HYPERION trial data to assess potential associations linking postresuscitation shock after non-shockable cardiac arrest to hypothermia at 33 °C on favourable functional outcome.

METHODS: We divided the patients into groups with vs. without postresuscitation (defined as the need for vasoactive drugs) shock then assessed the proportion of patients with a favourable functional outcome (day-90 Cerebral Performance Category [CPC] 1 or 2) after hypothermia (33 °C) vs. controlled normothermia (37 °C) in each group. Patients with norepinephrine or epinephrine > 1 µg/kg/min were not included.

RESULTS: Of the 581 patients included in 25 ICUs in France and who did not withdraw consent, 339 had a postresuscitation shock and 242 did not. In the postresuscitation-shock group, 159 received hypothermia, including 14 with a day-90 CPC of 1-2, and 180 normothermia, including 10 with a day-90 CPC of 1-2 (8.81% vs. 5.56%, respectively; P = 0.24). After adjustment, the proportion of patients with CPC 1-2 also did not differ significantly between the hypothermia and normothermia groups (adjusted hazards ratio, 1.99; 95% confidence interval, 0.72-5.50; P = 0.18). Day-90 mortality was comparable in these two groups (83% vs. 86%, respectively; P = 0.43).

CONCLUSIONS: After non-shockable cardiac arrest, mild-to-moderate postresuscitation shock at intensive-care-unit admission did not seem associated with day-90 functional outcome or survival. Therapeutic hypothermia at 33 °C was not associated with worse outcomes compared to controlled normothermia in patients with postresuscitation shock. Trial registration ClinicalTrials.gov, NCT01994772.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Ziriat I, Le Thuaut A, Colin G, et al. Outcomes of mild-to-moderate postresuscitation shock after non-shockable cardiac arrest and association with temperature management: a post hoc analysis of HYPERION trial data. Ann Intensive Care. 2022. PMID: 36251223. doi:10.1186/s13613-022-01071-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。